Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human IMGN151 trial in recurrent gynecologic cancers
NL-OMON60877Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of opugotamig olatansine in endometrial cancer (EC), epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and 2 more (7 arms), sponsored by AbbVie Inc. Primary endpoints: Incidence of adverse events, serious adverse events, and dose-limiting toxicities and Recommended dose of IMGN151 monotherapy. Started May 2025; status: active, not recruiting.
02
Drugs
opugotamig olatansine
03
Conditions
endometrial cancer (EC)epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON60877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60877.